MedTrace Logo

A Multicenter Prospective Study of Application of Platelet Mapping in Acute-on-chronic-liver Failure in China

NCT04119973 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 486

Last updated 2020-01-09

No results posted yet for this study

Summary

Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin production and provides a global assessment of coagulation incorporating the cumulative effect of the interactions at various levels between plasma components and cellular component of coagulation. And through the platelet mapping, it can help provide a picture of patients' function of platelet. Based on the primary result of our derivation cohort(NCT03281278), ACLF patients with high ADP inhibition rate had high 28-day mortality.This multicenter validation cohort aims to validate the predictive role of platelet mapping in ACLF prognosis, organ failure developments and short term mortality.

Conditions

  • Thrombelastography
  • Acute on Chronic Liver Failure
  • Platelet
  • Multicenter Prospective Study

Interventions

OTHER

standard treatment

standard medical treatment

Sponsors & Collaborators

  • Southwest Hospital, China

    collaborator OTHER

  • The First Hospital of Jilin University

    collaborator OTHER

  • First Affiliated Hospital of Xinjiang Medical University

    collaborator OTHER

  • Meng Chao Hepatobiliary Hospital of Fujian Medical University

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Taihe Hospital

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-16
Primary Completion
2019-08-04
Completion
2019-11-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04119973 on ClinicalTrials.gov